Abstract

Type 2 diabetes mellitus (T2DM) affects approximately 537 million adults globally, with projections indicating 783 
million cases by 2045, driving substantial cardiovascular and renal morbidity. Monotherapy with glucagon-like 
peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter-2 inhibitors (SGLT2i) provided glycemic 
control alongside organ-protective benefits, yet many patients fail to achieve composite metabolic targets. This 
narrative review critically evaluated the biochemical rationale, clinical evidence, and safety profile of combining 
GLP-1RAs with SGLT2i in T2DM management. A comprehensive literature search was conducted in PubMed, 
Embase, and Web of Science databases covering January 2017 through March 2025, focusing on randomized 
controlled trials, meta-analyses, and mechanistic studies. Current evidence demonstrated that combination therapy 
produces complementary mechanisms through incretin-mediated insulin secretion enhancement and renal glucose 
excretion, achieving superior HbA1c reductions (mean additional 0.6--1.2% beyond monotherapy), greater weight 
loss (3--5 kg additional reduction), and enhanced cardiovascular and renal protection with hazard ratios of 0.78-
0.88 for major adverse cardiovascular events compared to either agent alone. Safety profiles showed acceptable 
tolerability with predominantly gastrointestinal and genitourinary adverse events that diminished over time, though 
cost considerations and long-term real-world effectiveness require further investigation. Combination GLP-1RA 
and SGLT2i therapy represented an evidence-based strategy for comprehensive T2DM management, offering 
synergistic metabolic and cardio-renal benefits that align with contemporary treatment paradigms emphasizing 
organ protection beyond glycemic control.